David Rizzieri

David Rizzieri

UNVERIFIED PROFILE

Are you David Rizzieri?   Register this Author

Register author
David Rizzieri

David Rizzieri

Publications by authors named "David Rizzieri"

Are you David Rizzieri?   Register this Author

100Publications

3564Reads

11Profile Views

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.

Haematologica 2019 09 26. Epub 2019 Sep 26.

Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.220756DOI Listing
September 2019

Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome.

Clin Cancer Res 2019 Jul 5;25(13):4155-4167. Epub 2019 Apr 5.

Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800136PMC
July 2019

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

N Engl J Med 2019 04;380(17):1628-1637

From the University of Texas M.D. Anderson Cancer Center, Houston (N.P., M.D., H.M.K., M.K.); Dana-Farber Cancer Institute (A.A.L.) and Boston University School of Medicine (J.M.S.), Boston, and Veristat, Southborough (J.B.) - all in Massachusetts; H. Lee Moffitt Cancer Center, Tampa, FL (K.L.S., J.E.L.); City of Hope National Medical Center, Duarte, CA (A.S.S.); Ohio State University, Columbus (S.V.); Winship Cancer Institute of Emory University, Atlanta (W.B.); Duke University Medical Center, Durham, NC (D.A.R.); and Roswell Park Comprehensive Cancer Center, Buffalo (E.S.W.), and Stemline Therapeutics, New York (S. Spence, S. Shemesh, C.L.B., I.B.) - both in New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1815105DOI Listing
April 2019

Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

Clin Lymphoma Myeloma Leuk 2018 10 29;18(10):679-686. Epub 2018 Jul 29.

Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.07.285DOI Listing
October 2018

Treatment of blastic plasmacytoid dendritic cell neoplasm.

Hematology Am Soc Hematol Educ Program 2016 Dec;2016(1):16-23

Duke Cancer Institute, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2016.1.16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142460PMC
December 2016

CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.

Cancer Cell 2016 Nov 27;30(5):792-805. Epub 2016 Oct 27.

Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.10.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137811PMC
November 2016

Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.

Eur J Haematol 2016 Oct 31;97(4):313-20. Epub 2016 May 31.

Division of Hematologic Malignancies & Cellular Therapy, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12771DOI Listing
October 2016

Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?

Authors:
David Rizzieri

Crit Rev Oncol Hematol 2016 Sep 16;105:5-17. Epub 2016 Jul 16.

Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, 20 Duke Medicine Circle, Durham NC 27710, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2016.07.008DOI Listing
September 2016

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity.

Adv Radiat Oncol 2016 Oct-Dec;1(4):272-280. Epub 2016 Jul 15.

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2016.07.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514157PMC
July 2016

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

J Clin Oncol 2016 06 4;34(16):1864-71. Epub 2016 Apr 4.

Brian C. Shaffer and Martin Tallman, Memorial Sloan Kettering Cancer Center; Adriana K. Malone, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai; Ran Reshef, Columbia University Medical Center, New York; Mark Litzow, Mayo Clinic Rochester; Jane Liesveld, University of Rochester Medical Center, Rochester; Peter H. Wiernik, Our Lady of Mercy Medical Center, Bronx, NY; Kwang Woo Ahn, Zhen-Huan Hu, and Wael Saber, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI; Taiga Nishihori and Mohamed A. Kharfan-Dabaja, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; David Valcárcel, Hospital Vall d'Hebron, Barcelona, Spain; Michael R. Grunwald, Omotayo Fasan, and Edward Copelan, Levine Cancer Institute, Carolinas HealthCare System, Charlotte; William Allen Wood, University of North Carolina at Chapel Hill, Chapel Hill; David A. Rizzieri, Duke University Medical Center, Durham, NC; Ulrike Bacher, University of Medicine Göttingen, Göttingen, Germany; Betty Hamilton and Aaron Gerds, Cleveland Clinic Taussig Cancer Institute; Matt Kalaycio and Ron Sobecks, Cleveland Clinic Foundation, Cleveland; Basem William, Ohio State University Medical Center, Columbus, OH; Ayman Saad and Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Corey Cutler and Edwin Alyea, Dana-Farber Cancer Institute, Boston, MA; Erica Warlick and Celalettin Ustun, University of Minnesota Medical Center, Minneapolis, MN; Baldeep Mona Wirk, Seattle Cancer Care Alliance, Seattle, WA; Mitchell Sabloff, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario; Andrew Daly, Tom Baker Cancer Center, Calgary, Alberta, Canada; David Marks, University Hospitals Bristol National Health Service Trust, Bristol; Robert Peter Gale, Imperial College London, London, United Kingdom; Richard Olsson, Karolinska Institutet, Stockholm, Sweden; Alan M. Miller, Baylor University Medical Center; Rammurti Kamble

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0515DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966345PMC
June 2016

Individualizing treatment decisions for older adults with hematologic malignancies.

Am Soc Clin Oncol Educ Book 2013 :208-19

From the Comprehensive Cancer Center of Wake Forest University, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC; Department of Medicine, Division of Hematologic Malignancies and Cell Therapy, Duke University Medical Center, Durham, NC; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy; Department I of Internal Medicine and Center of Integrated Oncology Köln Bonn, University of Cologne, Köln, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.208DOI Listing
April 2016

Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders.

Adv Hematol 2016 2;2016:1423493. Epub 2016 Feb 2.

Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/1423493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754478PMC
March 2016

Immunotherapeutic applications of NK cells.

Pharmaceuticals (Basel) 2015 May 25;8(2):250-6. Epub 2015 May 25.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ph8020250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491659PMC
May 2015

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.

J Clin Oncol 2015 Apr 2;33(11):1252-7. Epub 2015 Mar 2.

Richard M. Stone, Emanuele Mazzola, and Donna Neuberg, Dana-Farber Cancer Institute, Boston; Ante S. Lundberg, Antisoma, Cambridge, MA; Steven L. Allen, Hofstra North Shore-Long Island Jewish School of Medicine, Lake Success; Meir Wetzler, Roswell Park Cancer Institute, Buffalo; Martin S. Tallman, Memorial Sloan Kettering Cancer Center, New York, NY; Arnaud Pigneux, Hopital Haut-Leveque, Pessac, France; Robert K. Stuart, Medical University of South Carolina, Charleston, SC; David Rizzieri, Duke University Medical Center, Durham; Bayard Powell, Wake Forest University Comprehensive Cancer Center, Winston Salem, NC; Harry P. Erba, University of Michigan Health System, Ann Arbor, MI; Lloyd Damon, University of California San Francisco, San Francisco, CA; Jun-Ho Jang, Samsung Medical Center, Seoul, Korea; Krzysztof Warzocha, Institute of Hematology and Transfusiology, Warsaw, Poland; Támas Masszi, Szent Istvan and Szent Laszlo Corporate Hospital, Budapest; Miklos Egyed, Kaposi Mor County Teaching Hospital, Kasposvar, Hungary; Mikkael A. Sekeres, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Heinz-August Horst, Universitatsklinikum Schleswig-Holstein, Kiel, Germany; Dominik Selleslag, Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium; Scott R. Solomon, Blood and Marrow Transplant Program and Northside Hospital, Atlanta, GA; and Parameswaran Venugopal, Rush University Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/02/26/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.0952
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.0952DOI Listing
April 2015

Safety of growth factor administration for leukapheresis in those with WBC counts greater than 60,000/µl.

J Clin Apher 2015 Feb 28;30(1):28-31. Epub 2014 Jun 28.

Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jca.21343DOI Listing
February 2015

Clinical potential of elacytarabine in patients with acute myeloid leukemia.

Ther Adv Hematol 2014 Dec;5(6):211-20

Duke University Medical Center - Medicine, 1149 North Pavilion Duke University Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620714552615DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4250268PMC
December 2014

Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia.

Nat Genet 2014 Mar 2;46(3):245-52. Epub 2014 Feb 2.

1] Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California, USA. [2] Sanford Consortium for Regenerative Medicine, La Jolla, California, USA. [3] Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA. [4] Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.2889DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267534PMC
March 2014

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.

Biol Blood Marrow Transplant 2014 Feb 20;20(2):257-63. Epub 2013 Nov 20.

Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.11.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140655PMC
February 2014

Is timing everything?

Authors:
David Rizzieri

Biol Blood Marrow Transplant 2014 Feb 14;20(2):145-6. Epub 2013 Dec 14.

Duke University Medical Center, Durham, North Carolina. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.12.556DOI Listing
February 2014

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.

J Clin Oncol 2014 Feb 16;32(4):273-81. Epub 2013 Dec 16.

Timothy S. Fenske and Mehdi Hamadani, Medical College of Wisconsin; Mei-Jie Zhang, Jeanette Carreras, and Parameswaran N. Hari, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI; Ernesto Ayala, H. Lee Moffitt Cancer Center and Research Institute, Tampa; Baldeep M. Wirk, Shands Healthcare and University of Florida, Gainesville, FL; Linda J. Burns, University of Minnesota Medical Center, Fairview, Minneapolis; David J. Inwards, Mayo Clinic Rochester, Rochester, MN; Amanda Cashen, Barnes Jewish Hospital, Washington University School of Medicine, St. Louis, MO; Luciano J. Costa, Medical University of South Carolina, Charleston, SC; César O. Freytes, South Texas Veterans Health Care System and University of Texas Health Science Center, San Antonio, TX; Robert P. Gale, Imperial College; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Leona A. Holmberg and David G. Maloney, Fred Hutchinson Cancer Research Center, Seattle, WA; Hillard M. Lazarus, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Reinhold Munker, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA; Miguel-Angel Perales, Memorial Sloan-Kettering Cancer Center, New York, NY; David A. Rizzieri, Duke University Medical Center, Durham, NC; Harry C. Schouten, Academische Ziekenhuis Maastricht, Maastricht, the Netherlands; Sonali M. Smith, University of Chicago Hospitals, Chicago, IL; Edmund K. Waller, Emory University Hospital, Atlanta, GA; and Ginna G. Laport, Stanford Hospital and Clinics, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.2454DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897255PMC
February 2014

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

J Clin Oncol 2013 Nov 14;31(33):4199-206. Epub 2013 Oct 14.

Philippe Armand and Edie Weller, Dana-Farber Cancer Institute; David E. Avigan, Beth Israel Deaconess Medical Center; Yi-Bin Chen, Massachusetts General Hospital, Boston, MA; Arnon Nagler, Chaim Sheba Medical Center, Tel-Hashomer; Reuven Or, Hadassah Medical Center, Jerusalem; Rinat Rotem-Yehudar, CureTech, Yavne, Israel; Steven M. Devine, The Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus; Hillard M. Lazarus, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; Mark S. Kaminski, University of Michigan, Ann Arbor, MI; H. Kent Holland, Northside Hospital; Edmund K. Waller, Winship Cancer Institute, Emory University, Atlanta, GA; Jane N. Winter and Leo I. Gordon, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine; Stephanie A. Gregory, Rush Medical Center, Chicago, IL; James R. Mason, Scripps Clinic; Edward D. Ball, Moores University of California at San Diego Cancer Center, University of California, San Diego; John M. Timmerman and David Andorsky, University of California, Los Angeles, Los Angeles, CA; Joseph W. Fay, Baylor Research Institute, Baylor University Medical Center, Dallas; Chitra M. Hosing, The University of Texas MD Anderson Cancer Center, Houston, TX; David A. Rizzieri, Duke Cancer Center, Durham, NC; Joseph P. Uberti, Karmanos Cancer Institute, Detroit, MI; Markus Y. Mapara, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.48.3685
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.48.3685DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878008PMC
November 2013

Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.

Proc Natl Acad Sci U S A 2013 Jun 4;110(25):E2298-307. Epub 2013 Jun 4.

Cancer and Stem Cell Biology Program, Duke-National University of Singapore Graduate Medical School, Singapore 169857.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1301838110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3690864PMC
June 2013

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.

Lancet Oncol 2013 Apr 28;14(4):354-62. Epub 2013 Feb 28.

Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70037-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557006PMC
April 2013

Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Proc Natl Acad Sci U S A 2013 Feb 16;110(6):2300-5. Epub 2013 Jan 16.

Department of Pharmacology and Toxicology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1206551110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568344PMC
February 2013

New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.

Int J Hematol Oncol 2013 Feb;2(1)

Division of Hematologic Malignancies & Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijh.13.4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841006PMC
February 2013

MDS: unraveling the mystery.

Authors:
David A Rizzieri

Blood 2012 Dec;120(25):4906-8

Duke Cancer Institute.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-09-452755DOI Listing
December 2012

Chemoimmunotherapy's potential to impact paroxysmal nocturnal hemoglobinuria.

Clin Adv Hematol Oncol 2012 Feb;10(2):136-7

Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
February 2012

Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.

Int J Radiat Oncol Biol Phys 2011 Nov 6;81(3):812-8. Epub 2010 Oct 6.

Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03603016100094
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2010.06.058DOI Listing
November 2011

Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Biol Blood Marrow Transplant 2011 Jun 22;17(6):867-74. Epub 2010 Sep 22.

Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2010.09.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877679PMC
June 2011

Alemtuzumab for the prevention and treatment of graft-versus-host disease.

Int J Hematol 2011 May 3;93(5):586-593. Epub 2011 Mar 3.

Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 1100, Durham, NC, 27705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-011-0802-2DOI Listing
May 2011

Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL).

Br J Haematol 2011 May 6;153(4):504-7. Epub 2011 Mar 6.

Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2011.08607.xDOI Listing
May 2011

Haploidentical transplantation for leukemia.

Curr Oncol Rep 2010 Sep;12(5):292-301

Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-010-0113-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874937PMC
September 2010

Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.

J Clin Oncol 2009 Nov 26;27(33):5580-6. Epub 2009 Oct 26.

Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27708, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.22.2547DOI Listing
November 2009